<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00935246</url>
  </required_header>
  <id_info>
    <org_study_id>2008-12-042</org_study_id>
    <nct_id>NCT00935246</nct_id>
  </id_info>
  <brief_title>Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning</brief_title>
  <official_title>Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To reveal the genetic determinants of the treatment outcome of escitalopram in depressed
      patients (by using candidate gene approach and whole genome scanning).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purposes of this study are:

        1. To reveal the genetic determinants of the treatment outcome of escitalopram in depressed
           patients (by using candidate gene approach and whole genome scanning)

        2. To improve the success rate of escitalopram treatment response for depressed patients
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>antidepressant response at 2,4,6,8 weeks A/E monitoring at 1,2,4,6,8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>biological value at 0 week and 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Depression</condition>
  <condition>Continuous Antidepressant Abuse</condition>
  <condition>Adverse Reaction to Drug</condition>
  <arm_group>
    <arm_group_label>Antidepressant treated group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antidepressant treated group: depressed patients treated with Escitalopram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>other antidepressant treated group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>other Antidepressant treated group: depressed patients treated with other antidepressant without escitalopram</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose</description>
    <arm_group_label>Antidepressant treated group</arm_group_label>
    <other_name>Escitalopram : Lexapro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Eligible patients were enrolled in the clinical trials program of hte Samsung Medical
             Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a
             semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The
             affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the
             Korean version of the structured clinical interview for the diagnostic and statistical
             manual of mental disorders, Fourth edition.

          2. interview with one more patient's family member for objective diagnosis and final
             diagnosis decision by agreements of two more psychiatric physicians

        Exclusion Criteria:

          1. received psychotropic medication within 2 weeks of the study or fluoxetine within 4
             weeks

          2. potential study participants for pregnancy, significant medical conditions, abnormal
             laboratory baseline values, unstable psychiatric features(eg.suicidal), history of
             alcohol of drug dependence, seizures, head trauma with loss of consciousness,
             neurological illness, or concomitant Axis I psychiatric disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doh Kwan Kim, PhD, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Kangnam</city>
        <state>Seoul</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Doh Kwan Kim</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Genomic devices</keyword>
  <keyword>Prediction of Escitalopram Response</keyword>
  <keyword>Depressed Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

